These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4896835)

  • 1. [Allogenic bone marrow graft in man proved by 6 antigenic tracers after conditioning of the receiver and donor by antilymphocyte serum].
    Mathé G; Amiel JL; Schwarzenberg L; Schneider M; Cattan A; Schlumberger JR; Hayat M; de Vassal F; Jasmin C; Rosenfeld C; Choay J; Trolard P
    Rev Fr Etud Clin Biol; 1968 Dec; 13(10):1025-7. PubMed ID: 4896835
    [No Abstract]   [Full Text] [Related]  

  • 2. [Allogenic bone marrow graft after conditioning with only antilymphocytic serum in states of bone marrow aplasias].
    Amiel JL; Mathe G; Schwarzenberg L; Schneider M; Choay J; Trolard P; Hayat M; Schlumberger JR; Jasmin C
    Presse Med (1893); 1970 Sep; 78(40):1727-34. PubMed ID: 4394378
    [No Abstract]   [Full Text] [Related]  

  • 3. Isogeneic marrow grafts for hematologic malignancy in man.
    Rudolph RH; Fefer A; Thomas ED; Buckner CD; Clift RA; Storb R
    Arch Intern Med; 1973 Aug; 132(2):279-85. PubMed ID: 4268940
    [No Abstract]   [Full Text] [Related]  

  • 4. Bone marrow graft in man after conditioning by antilymphocytic serum.
    Mathé G; Amiel JL; Schwarzenberg L; Choay J; Trolard P; Schneider M; Hayat M; Schlumberger JR; Jasmin C
    Transplant Proc; 1971 Mar; 3(1):325-32. PubMed ID: 4106323
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone marrow transplantation after antilymphocyte globulin conditioning--split lymphocyte chimerism.
    Mathé G; Schwarzenberg L; Amiel JL; Schneider M; Belpomme D; Jasmin C; Rosenfeld C; Hayat M; de Vassal F; Steresco M
    Transplant Proc; 1972 Dec; 4(4):551-7. PubMed ID: 4566797
    [No Abstract]   [Full Text] [Related]  

  • 6. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia.
    Au WY; Chan AC; Lie AK; Chen FE; Liang R; Kwong YL
    Bone Marrow Transplant; 1998 Jan; 21(2):205-8. PubMed ID: 9489639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of the adaptability of donor myelokaryocytes after histocompatible marrow allografts under immunodepression].
    Poreshina LP; Liubimova LS; Tananov AT; Umbetkulova EK; Korenevskaia MI
    Probl Gematol Pereliv Krovi; 1980 Jul; 25(7):28-31. PubMed ID: 6995974
    [No Abstract]   [Full Text] [Related]  

  • 9. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes].
    Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ
    Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent infection with human T lymphotropic virus type 1 after allogeneic bone marrow transplantation from a seronegative donor.
    Kanda Y; Taketazu F; Chiba S; Yazaki Y; Hirai H
    Bone Marrow Transplant; 1999 Aug; 24(3):349. PubMed ID: 10455380
    [No Abstract]   [Full Text] [Related]  

  • 12. Donor leukocyte infusion for relapsed ANLL after allogeneic BMT and the use of interferon alpha to induce graft-versus-leukemia effect.
    Gürman G; Arslan O; Koç H; Akan H
    Bone Marrow Transplant; 1996 Oct; 18(4):825-6. PubMed ID: 8899208
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.
    Schleuning M; Günther W; Tischer J; Ledderose G; Kolb HJ
    Bone Marrow Transplant; 2003 Aug; 32(3):243-50. PubMed ID: 12858194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimerism and tolerance in rat recipients of intestinal allografts from ALS-treated donors with and without adjunct naïve-donor-strain bone-marrow cells.
    Nakao A; Nalesnik MA; Ishikawa T; Azhipa O; Demetris AJ; Murase N
    Transplantation; 2003 May; 75(9):1575-81. PubMed ID: 12792518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
    Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
    Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic bone marrow transplantation with a nonmyeloablative conditioning regimen in a patient with acute myeloblastic leukemia].
    Rossiev VA; Aleksandrova IIa; Lipshina SR; Stukalova TA; Savchenko VG
    Ter Arkh; 2000; 72(7):67. PubMed ID: 10983326
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Rischewski J; Sonnenberg S; Ayuk F; Tögel F; Schade U; Fiegel H; Erttmann R; Löliger C; Zander AR
    Bone Marrow Transplant; 2002 Apr; 29(8):683-9. PubMed ID: 12180114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta J; Powles R; Sirohi B; Treleaven J; Kulkarni S; Saso R; Tait D; Singhal S
    Bone Marrow Transplant; 2002 May; 29(10):853-9. PubMed ID: 12058235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.